Fc mutants with modified functional activity
Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.
1. A polypeptide comprising a mutated Fc region that has a functional activity mediated by the Fc region that is increased by a ratio of at least 15 compared to a parent polypeptide, wherein said functional activity mediated by the Fc region is selected from among antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), wherein the parent polypeptide comprises a Fc region of SEQ ID NO:1, and wherein said mutated Fc region has been modified by a combination of the mutations selected from:
(i) 248E and 378V;
(ii) 334N, 352S, 397M and 378V,
(iii) 2861, 378V and 423Y, and
(iv) 248E, 334R and 378V, compared to SEQ ID NO:1,
and wherein said mutated Fc region optionally has a maximum of two further mutations in SEQ ID NO:1, wherein one of them is on position 434, the numbering being that of the EU Index or Kabat equivalent.
2. The polypeptide according to claim 1 , having functional activity mediated by the Fc region that is increased compared with that of the parent polypeptide by a ratio of higher than 20.
3. The polypeptide according to claim 1 , wherein said mutated Fc region has an increased affinity for at least one of the receptors (FcRs) of the Fc region selected from among the C1q complement and FcgRIIIa (CD16a), FcgRIIa (CD32a) and FcgRIIb (CD32b) receptors.
4. A polypeptide comprising a mutated Fc region that has a functional activity mediated by the Fc region that is increased by a ratio of at least 15 compared to a parent polypeptide, wherein said functional activity mediated by the Fc region is selected from among antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), wherein the parent polypeptide comprises a Fc region of SEQ ID NO:1, and wherein the mutated Fc region has only been mutated at a combination of positions selected from:
248E and 378V;
334N, 352S, 397M and 378V,
2861, 378V and 423Y, and
248E, 334R and 378V,
compared to SEQ ID NO:1,
the numbering being that of the EU Index or Kabat equivalent.
5. The polypeptide according to claim 1 , wherein the polypeptide is selected from among an isolated Fc region, a sequence derived from an isolated Fc region, an antibody and a fusion protein comprising an Fc region.
6. The polypeptide according to claim 1 , wherein the polypeptide consists of an Fc region or consists of an antibody.
7. The polypeptide according to claim 1 , wherein the polypeptide is produced in the milk of transgenic animals.
8. A composition of polypeptides according to claim 1 , wherein the purified polypeptides of said composition, on their Asn297 glycosylation site, have N-glycans with a fucosylation rate lower than 65%.
9. The composition of polypeptides according to claim 8 , wherein the purified polypeptides of said composition, on their Asn297 glycosylation site, have a glycan structure of biantennary type with short chains, low sialylation, having non-intercalary terminal mannoses and/or terminal N-acetylglucosamines.
10. The composition of polypeptides according to claim 9 , wherein the purified polypeptides of said composition have a content higher than 60% for the G0+G1+G0F+G1F forms, the G0F+G1F forms being lower than 50%.
11. The composition of polypeptides according to claim 9 , wherein the purified polypeptides of said composition have a content higher than 60% for the G0+G1+G0F+G1F forms, the fucose content being lower than 65%.
12. A pharmaceutical composition comprising (i) a polypeptide according to claim 1 , and (ii) at least one pharmaceutically acceptable excipient.
13. The polypeptide according to claim 6 , wherein the polypeptide is an antibody directed against an antigen selected from among a tumour antigen, viral antigen, bacterial antigen, fungal antigen, a toxin, membrane-bound or circulating membrane, a membrane receptor.
14. A method to produce a polypeptide comprising an Fc region and having functional activity, mediated by the Fc region, that is increased compared with that of a parent polypeptide by a ratio of at least 15, wherein said functional activity mediated by the Fc region is selected from among antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and a combination of these activities, wherein the parent polypeptide comprises a Fc region of SEQ ID NO:1, said method comprising a step to introduce a combination of the following mutations, said combination being selected from among:
(i) the combination of mutations 248E and 378V;
(ii) the combination of mutations 334N, 352S, 397M and 378V,
(iii) the combination of mutations 2861, 378V and 423Y, or
(iv) the combination of mutations 248E, 334R and 378V,
and optionally 2 further mutations wherein one of them is on position 434, the numbering being that of the EU Index or Kabat equivalent.
15. The method according to claim 14 , wherein it comprises a step to introduce a combination of the following mutations, said combination being selected from among:
248E and 378V;
334N, 352S, 397M and 378V,
2861, 378V and 423Y, or
248E, 334R and 378V,
the numbering being that of the EU Index or Kabat equivalent.
16. The polypeptide according to claim 4 , wherein the polypeptide is selected from among an isolated Fc region, a sequence derived from an isolated Fc region, an antibody and a fusion protein comprising an Fc region.
17. The polypeptide according to claim 4 , wherein the polypeptide consists of an Fc region or consists of an antibody.
18. The polypeptide according to claim 4 , wherein the polypeptide is produced in the milk of transgenic animals.
19. A composition of polypeptides according to claim 4 , wherein the purified polypeptides of said composition, on their Asn297 glycosylation site, have N-glycans with a fucosylation rate lower than 65%.
20. The composition of polypeptides according to claim 19 , wherein the purified polypeptides of said composition, on their Asn297 glycosylation site, have a glycan structure of biantennary type with short chains, low sialylation, having non-intercalary terminal mannoses and/or terminal N-acetylglucosamines.
21. The composition of polypeptides according to claim 20 , wherein the purified polypeptides of said composition have a content higher than 60% for the G0+G1+G0F+G1F forms, the G0F+G1F forms being lower than 50%.
22. The composition of polypeptides according to claim 20 , wherein the purified polypeptides of said composition have a content higher than 60% for the G0+G1+G0F+G1F forms, the fucose content being lower than 65%.
23. A pharmaceutical composition comprising (i) a polypeptide according to claim 4 , and (ii) at least one pharmaceutically acceptable excipient.
24. The polypeptide according to claim 16 , wherein the polypeptide is an antibody directed against an antigen selected from among a tumour antigen, viral antigen, bacterial antigen, fungal antigen, a toxin, membrane-bound or circulating membrane, a membrane receptor.